United States Drug Pricing Report 2017 - The Rebating Bonanza

Dublin, Nov. 08, 2017 -- The "Drug Pricing in the US" report has been added to Research and Markets' offering.

Drug prices in the US have been the subject of intense debate over the past 2-3 years, following a surge in spending on prescription medicines and steep price increases in some categories. Public support for government action to curb prices is widespread.

President Donald Trump has vowed to intervene, and the federal government is expected to unveil pricing reform proposals during the second half of 2017.

In the meantime, state legislatures are debating a slew of bills designed to address prescription drug prices and curb pharmaceutical spending, while in the private sector, other stakeholders are keen to exert more control over a pricing agenda that is currently dominated by manufacturers and pharmacy benefit managers.

Key Topics Covered:

1 EXECUTIVE SUMMARY

• Paying the price for unrivaled access to prescription drugs
• Rebating has fueled a period of dramatic list price inflation
• Winners and losers under the current system
• Prospects for change

2 THE PRICING DEBATE RESURFACES

• A familiar problem that never went away
• Bibliography

3 PUBLIC SECTOR PRICES

• Not so free in practice
• Labyrinthine rules limit public purchasing and reimbursement prices
• The public sector drugs bill is still rising rapidly
• Bibliography

4 PRIVATE SECTOR PRICES

• Where market forces truly do run free
• PBMs - the pharmaceutical industry's main adversary
• PBM pressure has driven a rebating arms race
• Bibliography

5 THE REBATING BONANZA

• A solution, or part of the problem?
• List prices versus net prices: the gap becomes a gulf
• List price hikes have been used to create headroom for rebates
• Rebates soar, but net prices still comfortably outpace inflation
• Resetting the drug pricing debate
• Winners and losers under the current system
• Bibliography

6 DRUG PRICE REFORM PROSPECTS

• How might the drug pricing debate play out?
• Public support for pricing intervention is strong
• Public program prices and spending top the federal agenda
• Federal inaction prompts states to begin legislating on prices
• Market dynamics in the private sector begin to shift
• Seeking value for money
• Endgame scenarios
• Bibliography

7 APPENDIX

For more information about this report visit https://www.researchandmarkets.com/research/st97s3/drug_pricing_in

CONTACT: Research and Markets
         Laura Wood, Senior Manager
         [email protected]
         For E.S.T Office Hours Call 1-917-300-0470
         For U.S./CAN Toll Free Call 1-800-526-8630
         For GMT Office Hours Call +353-1-416-8900
         Related Topics: Pharmacoeconomics